Nxera partners with Handok for Pivlaz distribution

15 April 2024

Japanese drugmaker Nxera Pharma (TYO 4565) has entered into an exclusive supply and distribution agreement with Handok Pharmaceuticals to commercialize Pivlaz (clazosentan sodium) 150mg in South Korea.

Under the terms of the agreement, Nxera Pharma Korea (NPK) will provide drug product to Handok at an agreed price and Handok is exclusively responsible for the promotion, marketing, sales and distribution of Pivlaz in South Korea.

Until recently known as Sosei Group or Sosei Heptares, Nxera will receive a one-off upfront payment from Handok on signing of the agreement and is eligible for further commercial milestone payments plus sales coming from product supply.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK